PHASQ (PhaseBio Pharmaceuticals) Total Assets : $22.17 Mil (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals Total Assets?

PhaseBio Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2022 was $22.17 Mil.

Total Assets is connected with ROA %. PhaseBio Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2022 was -219.17%. Total Assets is also linked to Revenue through Asset Turnover. PhaseBio Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2022 was 0.01.

PhaseBio Pharmaceuticals Total Assets Historical Data

The historical data trend for PhaseBio Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseBio Pharmaceuticals Total Assets Chart

PhaseBio Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Assets

Get a 7-Day Free Trial

14.10

63.03

82.49

50.36

60.54

PhaseBio Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Apr24
Total Assets	Get a 7-Day Free Trial															77.73	60.54	38.66	22.17	2.59

PhaseBio Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

PhaseBio Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	-93.034	+	153.574
	=	60.54

PhaseBio Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2022 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2022 )	+	Total Liabilities (Q: Jun. 2022 )
	=	-117.398	+	139.564
	=	22.17

PhaseBio Pharmaceuticals (OTCPK:PHASQ) Total Assets Explanation

Total Assets is connected with ROA %.

PhaseBio Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2022 is

ROA %	=	Net Income (Q: Jun. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
	=	-66.66	/	( (38.664	+	22.166)	/ 2 )
	=	-66.66	/	30.415
	=	-219.17 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

PhaseBio Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2022 is

	Asset Turnover
=	Revenue (Q: Jun. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
=	0.208	/	( (38.664	+	22.166)	/ 2 )
=	0.208	/	30.415
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

PhaseBio Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseBio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355

Website

https://www.phasebio.com

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.

Executives

New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt	officer: VP, Human Resources	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall	officer: Chief Commercial Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp	director	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance	officer: VP, Research and Sci. Affairs	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York	officer: VP, Corporate Development	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee	officer: Chief Medical Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold	officer: VP, Preclinical and Chem	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson	officer: VP, Head of Legal	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355